星元未来的个人主页 - 老虎社区

星元未来

星元未来

暂无个人介绍

IP属地：北京

6关注

2粉丝

0主题

0勋章

2024-06-01

5毛多赶快跑。

贾跃亭：说“法拉第未来永远无法盈利”是造谣

2024-05-30

$Faraday Future(FFIE)$ 昨天让我说中了，昨天我发布。快跑，昨天5毛今天3毛，现在预测一个月内几分钱

2024-03-19

说说你对这篇新闻的看法...

抱歉，原内容已删除

2024-03-06

说说你对这篇新闻的看法...

抱歉，原内容已删除

2024-03-02

，

“减肥新药”卖爆，销售额同比增363%！小摩：2030年销售额将超千亿美元

2024-03-02

$Faraday Future(FFIE)$ 过两个月再三合一，再打到0.10就变成一分一股了最后清零退市

2024-02-07

$Faraday Future(FFIE)$

2022-12-23

说说你对这篇新闻的看法...

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4097226743085970","uuid":"4097226743085970","gmtCreate":1634123826679,"gmtModify":1663292506888,"name":"星元未来","pinyin":"xywlxingyuanweilai","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/3a8e915d7f808030bbf9731d84347a96","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":6,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.12","exceedPercentage":"80.37%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.08","exceedPercentage":"80.59%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"北京","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":311893716779120,"gmtCreate":1717180060098,"gmtModify":1717180062091,"author":{"id":"4097226743085970","authorId":"4097226743085970","name":"星元未来","avatar":"https://static.tigerbbs.com/3a8e915d7f808030bbf9731d84347a96","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097226743085970","authorIdStr":"4097226743085970"},"themes":[],"htmlText":"5毛多 赶快跑。","listText":"5毛多 赶快跑。","text":"5毛多 赶快跑。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/311893716779120","repostId":"2439932194","repostType":2,"repost":{"id":"2439932194","kind":"highlight","pubTimestamp":1717136276,"share":"https://www.laohu8.com/m/news/2439932194?lang=&edition=full","pubTime":"2024-05-31 14:17","market":"us","language":"zh","title":"贾跃亭：说“法拉第未来永远无法盈利”是造谣","url":"https://stock-news.laohu8.com/highlight/detail?id=2439932194","media":"金融界","summary":"坚信FF可能成为更早实现盈利的公司之一。","content":"<html><head></head><body><p>5月31日，贾跃亭发布关于2023财报“风险提示披露”造成误解和谣言的澄清视频，称“贾跃亭和FF承认公司永远无法盈利”是造谣，坚信FF可能成为更早实现盈利的公司之一。</p><p>贾跃亭称：“贾跃亭和FF承认公司永远无法盈利”完全不属实，这是对我们财报风险披露部分中一句话‘It may never achieve or sustain profitability’的断章取义甚至造谣，其实这些风险描述中的大多数都可以追溯到公司上市前向SEC提交的注册文件当中，从那以后那些风险描述就沿用到每一份的披露文件当中，在所有与过往的披露文件中都可以查到，这些都是年报风险提示的通常做法。只是公司主动选择了最严格的合规标准，对潜在风险做出了最极端的描述，而这不是已经发生的事实，更不存在所谓的承认。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a6e182f7ef8b7b40cf7d705958e40481\" title=\"\" tg-width=\"631\" tg-height=\"510\"/></p><p></p></body></html>","source":"jinrongjie_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>贾跃亭：说“法拉第未来永远无法盈利”是造谣</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n贾跃亭：说“法拉第未来永远无法盈利”是造谣\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-31 14:17 北京时间&nbsp;&nbsp;&nbsp;<a href=https://usstock.jrj.com.cn/2024/05/31141740845737.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月31日，贾跃亭发布关于2023财报“风险提示披露”造成误解和谣言的澄清视频，称“贾跃亭和FF承认公司永远无法盈利”是造谣，坚信FF可能成为更早实现盈利的公司之一。贾跃亭称：“贾跃亭和FF承认公司永远无法盈利”完全不属实，这是对我们财报风险披露部分中一句话‘It may never achieve or sustain profitability’的断章取义甚至造谣，其实这些风险描述中的大多数都...</p>\n\n<a href=\"https://usstock.jrj.com.cn/2024/05/31141740845737.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1a3754f388f30b5f7e5d59651613a82b","relate_stocks":{},"source_url":"https://usstock.jrj.com.cn/2024/05/31141740845737.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2439932194","content_text":"5月31日，贾跃亭发布关于2023财报“风险提示披露”造成误解和谣言的澄清视频，称“贾跃亭和FF承认公司永远无法盈利”是造谣，坚信FF可能成为更早实现盈利的公司之一。贾跃亭称：“贾跃亭和FF承认公司永远无法盈利”完全不属实，这是对我们财报风险披露部分中一句话‘It may never achieve or sustain profitability’的断章取义甚至造谣，其实这些风险描述中的大多数都可以追溯到公司上市前向SEC提交的注册文件当中，从那以后那些风险描述就沿用到每一份的披露文件当中，在所有与过往的披露文件中都可以查到，这些都是年报风险提示的通常做法。只是公司主动选择了最严格的合规标准，对潜在风险做出了最极端的描述，而这不是已经发生的事实，更不存在所谓的承认。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1557,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":311285470867576,"gmtCreate":1717017398812,"gmtModify":1717017400769,"author":{"id":"4097226743085970","authorId":"4097226743085970","name":"星元未来","avatar":"https://static.tigerbbs.com/3a8e915d7f808030bbf9731d84347a96","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097226743085970","authorIdStr":"4097226743085970"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$&nbsp;</a> 昨天让我说中了，昨天我发布。快跑，昨天5毛今天3毛，现在预测 一个月内几分钱","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$&nbsp;</a> 昨天让我说中了，昨天我发布。快跑，昨天5毛今天3毛，现在预测 一个月内几分钱","text":"$Faraday Future(FFIE)$ 昨天让我说中了，昨天我发布。快跑，昨天5毛今天3毛，现在预测 一个月内几分钱","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/311285470867576","isVote":1,"tweetType":1,"viewCount":2427,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3500480192324777","authorId":"3500480192324777","name":"新声代韭菜","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"idStr":"3500480192324777","authorIdStr":"3500480192324777"},"content":"然后80合一[微笑]","text":"然后80合一[微笑]","html":"然后80合一[微笑]"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":285845362696264,"gmtCreate":1710804866314,"gmtModify":1710804868053,"author":{"id":"4097226743085970","authorId":"4097226743085970","name":"星元未来","avatar":"https://static.tigerbbs.com/3a8e915d7f808030bbf9731d84347a96","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097226743085970","authorIdStr":"4097226743085970"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/285845362696264","repostId":"2419901249","repostType":2,"isVote":1,"tweetType":1,"viewCount":1277,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":281170214961272,"gmtCreate":1709675695111,"gmtModify":1709675696781,"author":{"id":"4097226743085970","authorId":"4097226743085970","name":"星元未来","avatar":"https://static.tigerbbs.com/3a8e915d7f808030bbf9731d84347a96","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097226743085970","authorIdStr":"4097226743085970"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/281170214961272","repostId":"2387141327","repostType":2,"isVote":1,"tweetType":1,"viewCount":2203,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":279796308074616,"gmtCreate":1709331062713,"gmtModify":1709334215160,"author":{"id":"4097226743085970","authorId":"4097226743085970","name":"星元未来","avatar":"https://static.tigerbbs.com/3a8e915d7f808030bbf9731d84347a96","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097226743085970","authorIdStr":"4097226743085970"},"themes":[],"htmlText":"，","listText":"，","text":"，","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/279796308074616","repostId":"2366366393","repostType":2,"repost":{"id":"2366366393","kind":"highlight","pubTimestamp":1694406491,"share":"https://www.laohu8.com/m/news/2366366393?lang=&edition=full","pubTime":"2023-09-11 12:28","market":"hk","language":"zh","title":"“减肥新药”卖爆，销售额同比增363%！小摩：2030年销售额将超千亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2366366393","media":"格隆汇","summary":"国内药企争相布局","content":"<html><body><p><span>减肥药概念股</span>今日表现强劲<span>，</span><span><a href=\"https://laohu8.com/S/300255\">常山药业</a>20cm涨停，<a href=\"https://laohu8.com/S/301509\">金凯生科</a>涨超11%，<a href=\"https://laohu8.com/S/688117\">圣诺生物</a>、<a href=\"https://laohu8.com/S/301393\">昊帆生物</a>、<a href=\"https://laohu8.com/S/688076\">诺泰生物</a>等纷纷冲高。</span></p><p><img src=\"https://img3.gelonghui.com/38fc3-2e63da02-9795-4c8f-9280-98ef2739f0c8.png\"/></p><p>近日司美格鲁肽（商品名：Wegovy）等减肥新药热卖引市场关注，丹麦制药巨头<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>（novo nordisk）超越奢侈品巨头LVMH，成为欧洲市值最高的公司。<span><a href=\"https://laohu8.com/S/LLY\">礼来</a>股价也连番大涨，目前市值已超5500亿美元，是<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>的两倍多。</span></p><p>此外，<a href=\"https://laohu8.com/S/JPM\">摩根大通</a>提高了对减肥药的销售额预测，预计到2030年这种GLP-1激动剂类药物的年销售额将超过1000亿美元，诺和诺德、礼来总市值不断刷创新高。<span><a href=\"https://laohu8.com/S/600030\">中信证券</a>测算，2030年中国减肥用GLP-1受体激动剂的市场规模将达到383亿元。</span></p><h3><font color=\"#3daad6\"><br/></font></h3><h3><font color=\"#3daad6\">“减肥新药”卖爆</font></h3><h3><font color=\"#3daad6\">2023H1销售额同比增长363%</font></h3><div><font color=\"#3daad6\"><br/></font></div><p>2023年8月3日，<em>Science</em>杂志在线发表一篇题为“Turning the tide on obesity”的社论性文章，文中指出：<strong>全球现下有超过十亿人患有肥胖症，超重的比例甚至更多。</strong>随着新型高效减重药物的出现，科学家们正翘首以盼这类药物能否让“肥胖时代”的流行画上历史性的句号。</p><p>世界肥胖联盟在2023年3月公布了最新版《世界肥胖地图》报告，“预计2035年，全球将有超过40亿人超重/肥胖，占全球总人口的一半以上”。</p><p><span>另外一份数据显示，</span><span>帕博利珠单抗全球销售额超120亿美元，首次问鼎“药王”宝座；</span><b>降糖“新宠”司美格鲁肽销售额暴涨363%，一举迈入榜单前三。</b></p><p><img src=\"https://img3.gelonghui.com/0eafd-88f72ae4-2309-40ab-a2bb-571a3f48800f.png\"/></p><p>2023上半年全球畅销药品TOP10</p><p>资料显示，司美格鲁肽由诺和诺德研发，是一款同时获批肥胖和2型糖尿病双适应症的GLP-1激动剂。该药自2017年全球首次上市后，不到6年时间便跻身2023H1全球畅销药TOP3行列。</p><p>目前司美格鲁肽共有3款产品获批在售，分别为Ozempic（注射用降糖药）、Rybelsus（口服降糖药）、Wegovy（注射用减重药），得益于Wegovy销售额的突飞猛进，2023H1同比增长363%，2023上半年已突破90亿美元。<span></span></p><h3><font color=\"#3daad6\"><br/></font></h3><h3><font color=\"#3daad6\">国内多家药企公布GLP-1类药品研发进展</font></h3><div><font color=\"#3daad6\"><br/></font></div><p>6月3日，丹麦药企诺和诺德生产的司<b>美格鲁肽注射液</b>，对肥胖患者的适应症扩容正式获得国家药监局受理。在接下来一年内，该药物可能在国内获批上市。</p><p>据粗略统计，目前国内最少有25家企业，选择以减重为管线进行着GLP-1类药物的研发。</p><p><span>目前，我国唯一获批的GLP-1类减肥药，只有<a href=\"https://laohu8.com/S/000963\">华东医药</a>于今年7月份获批的</span><b>利拉鲁肽注射液。</b><span>司美格鲁肽国内进入3期的有齐鲁，华东，联邦，<a href=\"https://laohu8.com/S/01513\">丽珠医药</a>。</span><span><a href=\"https://laohu8.com/S/01801\">信达生物</a>IBI362（GLP-1R/GCGR 双靶点）目前处于临床3期阶段，恒瑞医药HRS953（GLP-1R/GIPR）临床2期中。</span></p><p><img src=\"https://img3.gelonghui.com/660ea-204a3144-a0bc-43e6-b2c3-5a07d1093e0d.png\"/></p><h3><font color=\"#3daad6\"><br/></font></h3><h3><font color=\"#3daad6\">小摩预测2030年年销售额将超1000亿美元</font></h3><div><font color=\"#3daad6\"><br/></font></div><p>摩根大通分析师Chris Schott表示，他不排除GLP-1在肥胖和糖尿病领域的销售额进一步上升的可能性，在社交媒体的大肆宣传下，这类药物的使用量正在迅速上升。<span></span></p><p>该行预计到2030年这种GLP-1激动剂类药物的年销售额将超过1000亿美元，诺和诺德和礼来形成双寡头垄断。<span></span></p><p><a href=\"https://laohu8.com/S/GS\">高盛</a>在报告中指出，肥胖每年给美国的医疗系统带来1700亿美元的成本，而到2035年，这种慢性疾病的影响将使全球GDP减少4万亿美元，相当于全球第四大经济体德国2022年的GDP，而以GLP-1类疗法为主的减肥药有望给这一趋势带来革命新的改变。</p><div></div><p>该行表示，减肥药物市场将从今年的刚刚超过50亿美元扩大到2030年的440亿美元，翻了近9倍，而这种增长将使诺和诺德和礼来的减肥药大幅受益。</p><p>高盛投资组合经理Jenny Chang表示，减肥药物市场“历史上一直受限”，而随着监管给更更多此类新药“亮绿灯”，使得这批有前景的新药完全可以进入市场。</p><p><a href=\"https://laohu8.com/S/601108\">财通证券</a>指出，相比于传统降糖、减重药物，GLP-1类药物兼具有效性高、安全性佳的优点，近年来利拉鲁肽、司美格鲁肽、替尔泊肽等品种相继上市，可以预计随着推动市场教育进一步加快，将促进GLP-1类药物在降糖、减重人群中渗透率不断提升。</p></body></html>","source":"gelonghui_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>“减肥新药”卖爆，销售额同比增363%！小摩：2030年销售额将超千亿美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n“减肥新药”卖爆，销售额同比增363%！小摩：2030年销售额将超千亿美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-09-11 12:28 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/p/643731><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>减肥药概念股今日表现强劲，常山药业20cm涨停，金凯生科涨超11%，圣诺生物、昊帆生物、诺泰生物等纷纷冲高。近日司美格鲁肽（商品名：Wegovy）等减肥新药热卖引市场关注，丹麦制药巨头诺和诺德（novo nordisk）超越奢侈品巨头LVMH，成为欧洲市值最高的公司。礼来股价也连番大涨，目前市值已超5500亿美元，是辉瑞的两倍多。此外，摩根大通提高了对减肥药的销售额预测，预计到2030年这种GLP...</p>\n\n<a href=\"https://www.gelonghui.com/p/643731\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://img3.gelonghui.com/23bd7-b1ea8c62-e16c-47da-8c4f-414c06832007.jpg","relate_stocks":{"300255":"常山药业","301393":"昊帆生物","301509":"金凯生科","688076":"诺泰生物","688117":"圣诺生物","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","01801":"信达生物","LU0971096721.USD":"富达环球金融服务 A","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","BK0196":"行业龙头","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK0132":"高送转概念","NVO":"诺和诺德","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","BK1589":"北水核心资产","BK4585":"ETF&股票定投概念","SG9999002232.USD":"Allianz Global High Payout USD","000963":"华东医药","BK4007":"制药","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4566":"资本集团","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","BK0229":"化学制品","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK0188":"融资融券","BK4550":"红杉资本持仓","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0187":"一线龙头","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","BK4207":"综合性银行","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0149725797.USD":"汇丰美国股市经济规模基金","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","BK1161":"生物科技","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","BK0175":"白马股","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","JPM":"摩根大通","LU0882574139.USD":"富达环球消费行业基金A ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC"},"source_url":"https://www.gelonghui.com/p/643731","is_english":false,"share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","article_id":"2366366393","content_text":"减肥药概念股今日表现强劲，常山药业20cm涨停，金凯生科涨超11%，圣诺生物、昊帆生物、诺泰生物等纷纷冲高。近日司美格鲁肽（商品名：Wegovy）等减肥新药热卖引市场关注，丹麦制药巨头诺和诺德（novo nordisk）超越奢侈品巨头LVMH，成为欧洲市值最高的公司。礼来股价也连番大涨，目前市值已超5500亿美元，是辉瑞的两倍多。此外，摩根大通提高了对减肥药的销售额预测，预计到2030年这种GLP-1激动剂类药物的年销售额将超过1000亿美元，诺和诺德、礼来总市值不断刷创新高。中信证券测算，2030年中国减肥用GLP-1受体激动剂的市场规模将达到383亿元。“减肥新药”卖爆2023H1销售额同比增长363%2023年8月3日，Science杂志在线发表一篇题为“Turning the tide on obesity”的社论性文章，文中指出：全球现下有超过十亿人患有肥胖症，超重的比例甚至更多。随着新型高效减重药物的出现，科学家们正翘首以盼这类药物能否让“肥胖时代”的流行画上历史性的句号。世界肥胖联盟在2023年3月公布了最新版《世界肥胖地图》报告，“预计2035年，全球将有超过40亿人超重/肥胖，占全球总人口的一半以上”。另外一份数据显示，帕博利珠单抗全球销售额超120亿美元，首次问鼎“药王”宝座；降糖“新宠”司美格鲁肽销售额暴涨363%，一举迈入榜单前三。2023上半年全球畅销药品TOP10资料显示，司美格鲁肽由诺和诺德研发，是一款同时获批肥胖和2型糖尿病双适应症的GLP-1激动剂。该药自2017年全球首次上市后，不到6年时间便跻身2023H1全球畅销药TOP3行列。目前司美格鲁肽共有3款产品获批在售，分别为Ozempic（注射用降糖药）、Rybelsus（口服降糖药）、Wegovy（注射用减重药），得益于Wegovy销售额的突飞猛进，2023H1同比增长363%，2023上半年已突破90亿美元。国内多家药企公布GLP-1类药品研发进展6月3日，丹麦药企诺和诺德生产的司美格鲁肽注射液，对肥胖患者的适应症扩容正式获得国家药监局受理。在接下来一年内，该药物可能在国内获批上市。据粗略统计，目前国内最少有25家企业，选择以减重为管线进行着GLP-1类药物的研发。目前，我国唯一获批的GLP-1类减肥药，只有华东医药于今年7月份获批的利拉鲁肽注射液。司美格鲁肽国内进入3期的有齐鲁，华东，联邦，丽珠医药。信达生物IBI362（GLP-1R/GCGR 双靶点）目前处于临床3期阶段，恒瑞医药HRS953（GLP-1R/GIPR）临床2期中。小摩预测2030年年销售额将超1000亿美元摩根大通分析师Chris Schott表示，他不排除GLP-1在肥胖和糖尿病领域的销售额进一步上升的可能性，在社交媒体的大肆宣传下，这类药物的使用量正在迅速上升。该行预计到2030年这种GLP-1激动剂类药物的年销售额将超过1000亿美元，诺和诺德和礼来形成双寡头垄断。高盛在报告中指出，肥胖每年给美国的医疗系统带来1700亿美元的成本，而到2035年，这种慢性疾病的影响将使全球GDP减少4万亿美元，相当于全球第四大经济体德国2022年的GDP，而以GLP-1类疗法为主的减肥药有望给这一趋势带来革命新的改变。该行表示，减肥药物市场将从今年的刚刚超过50亿美元扩大到2030年的440亿美元，翻了近9倍，而这种增长将使诺和诺德和礼来的减肥药大幅受益。高盛投资组合经理Jenny Chang表示，减肥药物市场“历史上一直受限”，而随着监管给更更多此类新药“亮绿灯”，使得这批有前景的新药完全可以进入市场。财通证券指出，相比于传统降糖、减重药物，GLP-1类药物兼具有效性高、安全性佳的优点，近年来利拉鲁肽、司美格鲁肽、替尔泊肽等品种相继上市，可以预计随着推动市场教育进一步加快，将促进GLP-1类药物在降糖、减重人群中渗透率不断提升。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1216,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":279713845416160,"gmtCreate":1709310955578,"gmtModify":1709312708208,"author":{"id":"4097226743085970","authorId":"4097226743085970","name":"星元未来","avatar":"https://static.tigerbbs.com/3a8e915d7f808030bbf9731d84347a96","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097226743085970","authorIdStr":"4097226743085970"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$&nbsp;</a>过两个月再三合一，再打到0.10就变成一分一股了最后清零退市","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$&nbsp;</a>过两个月再三合一，再打到0.10就变成一分一股了最后清零退市","text":"$Faraday Future(FFIE)$ 过两个月再三合一，再打到0.10就变成一分一股了最后清零退市","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/279713845416160","isVote":1,"tweetType":1,"viewCount":2377,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":271491973595304,"gmtCreate":1707319982817,"gmtModify":1707320227928,"author":{"id":"4097226743085970","authorId":"4097226743085970","name":"星元未来","avatar":"https://static.tigerbbs.com/3a8e915d7f808030bbf9731d84347a96","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097226743085970","authorIdStr":"4097226743085970"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$&nbsp;</a>","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$&nbsp;</a>","text":"$Faraday Future(FFIE)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/271491973595304","isVote":1,"tweetType":1,"viewCount":506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":621963335,"gmtCreate":1671810861927,"gmtModify":1671811143935,"author":{"id":"4097226743085970","authorId":"4097226743085970","name":"星元未来","avatar":"https://static.tigerbbs.com/3a8e915d7f808030bbf9731d84347a96","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097226743085970","authorIdStr":"4097226743085970"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/621963335","repostId":"1115397926","repostType":4,"isVote":1,"tweetType":1,"viewCount":2105,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":279713845416160,"gmtCreate":1709310955578,"gmtModify":1709312708208,"author":{"id":"4097226743085970","authorId":"4097226743085970","name":"星元未来","avatar":"https://static.tigerbbs.com/3a8e915d7f808030bbf9731d84347a96","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097226743085970","authorIdStr":"4097226743085970"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$&nbsp;</a>过两个月再三合一，再打到0.10就变成一分一股了最后清零退市","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$&nbsp;</a>过两个月再三合一，再打到0.10就变成一分一股了最后清零退市","text":"$Faraday Future(FFIE)$ 过两个月再三合一，再打到0.10就变成一分一股了最后清零退市","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/279713845416160","isVote":1,"tweetType":1,"viewCount":2377,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":311893716779120,"gmtCreate":1717180060098,"gmtModify":1717180062091,"author":{"id":"4097226743085970","authorId":"4097226743085970","name":"星元未来","avatar":"https://static.tigerbbs.com/3a8e915d7f808030bbf9731d84347a96","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097226743085970","authorIdStr":"4097226743085970"},"themes":[],"htmlText":"5毛多 赶快跑。","listText":"5毛多 赶快跑。","text":"5毛多 赶快跑。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/311893716779120","repostId":"2439932194","repostType":2,"repost":{"id":"2439932194","kind":"highlight","pubTimestamp":1717136276,"share":"https://www.laohu8.com/m/news/2439932194?lang=&edition=full","pubTime":"2024-05-31 14:17","market":"us","language":"zh","title":"贾跃亭：说“法拉第未来永远无法盈利”是造谣","url":"https://stock-news.laohu8.com/highlight/detail?id=2439932194","media":"金融界","summary":"坚信FF可能成为更早实现盈利的公司之一。","content":"<html><head></head><body><p>5月31日，贾跃亭发布关于2023财报“风险提示披露”造成误解和谣言的澄清视频，称“贾跃亭和FF承认公司永远无法盈利”是造谣，坚信FF可能成为更早实现盈利的公司之一。</p><p>贾跃亭称：“贾跃亭和FF承认公司永远无法盈利”完全不属实，这是对我们财报风险披露部分中一句话‘It may never achieve or sustain profitability’的断章取义甚至造谣，其实这些风险描述中的大多数都可以追溯到公司上市前向SEC提交的注册文件当中，从那以后那些风险描述就沿用到每一份的披露文件当中，在所有与过往的披露文件中都可以查到，这些都是年报风险提示的通常做法。只是公司主动选择了最严格的合规标准，对潜在风险做出了最极端的描述，而这不是已经发生的事实，更不存在所谓的承认。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a6e182f7ef8b7b40cf7d705958e40481\" title=\"\" tg-width=\"631\" tg-height=\"510\"/></p><p></p></body></html>","source":"jinrongjie_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>贾跃亭：说“法拉第未来永远无法盈利”是造谣</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n贾跃亭：说“法拉第未来永远无法盈利”是造谣\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-31 14:17 北京时间&nbsp;&nbsp;&nbsp;<a href=https://usstock.jrj.com.cn/2024/05/31141740845737.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月31日，贾跃亭发布关于2023财报“风险提示披露”造成误解和谣言的澄清视频，称“贾跃亭和FF承认公司永远无法盈利”是造谣，坚信FF可能成为更早实现盈利的公司之一。贾跃亭称：“贾跃亭和FF承认公司永远无法盈利”完全不属实，这是对我们财报风险披露部分中一句话‘It may never achieve or sustain profitability’的断章取义甚至造谣，其实这些风险描述中的大多数都...</p>\n\n<a href=\"https://usstock.jrj.com.cn/2024/05/31141740845737.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1a3754f388f30b5f7e5d59651613a82b","relate_stocks":{},"source_url":"https://usstock.jrj.com.cn/2024/05/31141740845737.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2439932194","content_text":"5月31日，贾跃亭发布关于2023财报“风险提示披露”造成误解和谣言的澄清视频，称“贾跃亭和FF承认公司永远无法盈利”是造谣，坚信FF可能成为更早实现盈利的公司之一。贾跃亭称：“贾跃亭和FF承认公司永远无法盈利”完全不属实，这是对我们财报风险披露部分中一句话‘It may never achieve or sustain profitability’的断章取义甚至造谣，其实这些风险描述中的大多数都可以追溯到公司上市前向SEC提交的注册文件当中，从那以后那些风险描述就沿用到每一份的披露文件当中，在所有与过往的披露文件中都可以查到，这些都是年报风险提示的通常做法。只是公司主动选择了最严格的合规标准，对潜在风险做出了最极端的描述，而这不是已经发生的事实，更不存在所谓的承认。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1557,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":285845362696264,"gmtCreate":1710804866314,"gmtModify":1710804868053,"author":{"id":"4097226743085970","authorId":"4097226743085970","name":"星元未来","avatar":"https://static.tigerbbs.com/3a8e915d7f808030bbf9731d84347a96","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097226743085970","authorIdStr":"4097226743085970"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/285845362696264","repostId":"2419901249","repostType":2,"isVote":1,"tweetType":1,"viewCount":1277,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":281170214961272,"gmtCreate":1709675695111,"gmtModify":1709675696781,"author":{"id":"4097226743085970","authorId":"4097226743085970","name":"星元未来","avatar":"https://static.tigerbbs.com/3a8e915d7f808030bbf9731d84347a96","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097226743085970","authorIdStr":"4097226743085970"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/281170214961272","repostId":"2387141327","repostType":2,"repost":{"id":"2387141327","kind":"highlight","weMediaInfo":{"introduction":"凤凰网港股","home_visible":1,"media_name":"凤凰网港股","id":"1002821290","head_image":"https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817"},"pubTimestamp":1701330532,"share":"https://www.laohu8.com/m/news/2387141327?lang=&edition=full","pubTime":"2023-11-30 15:48","market":"hk","language":"zh","title":"【券商聚焦】招银国际微削知乎(ZH)目标价至2美元 料会员业务增速放缓","url":"https://stock-news.laohu8.com/highlight/detail?id=2387141327","media":"凤凰网港股","summary":"金吾财讯 | 招银国际发研报指，知乎 3Q23业绩符合预期，收入同比增长12%，经调整净亏损收窄至2.25亿元人民币。经调整净亏损持续收窄，主要得益于毛利率的提升。展望4Q23，该行预计收入同比下降6%，经调整净亏损为2亿元人民币。职业教育和广告将因季节性和“双11”大促实现环比增长，而会员业务增速或因高基数而放缓。该行认为，知乎凭借在丰富的IP和内容库方面的优势，能够捕捉短剧和IP内容变现带来的机会。","content":"<html><body><p>金吾财讯 | 招银国际发研报指，<a href=\"https://laohu8.com/S/ZH\">知乎</a>(ZH)3Q23业绩符合预期，收入同比增长12%，经调整净亏损收窄至2.25亿元人民币。稳健的收入增速主要由强劲的会员业务（同比+39%）和职业教育（同比+86%）所拉动，但部分被疲软的广告业务（同比-17%）拖累。经调整净亏损持续收窄，主要得益于毛利率的提升。展望4Q23，该行预计收入同比下降6%，经调整净亏损为2亿元人民币。职业教育和广告将因季节性和“双11”大促实现环比增长，而会员业务增速或因高基数而放缓（预计同比增长11%）。该行认为，知乎凭借在丰富的IP和内容库方面的优势，能够捕捉短剧和IP内容变现带来的机会。此外，知乎在AI应用方面也取得了不错的进展，志海图AI的应用提高了内容生产力和用户体验。为了反映会员业务的放缓，该行将2023-25年收入下调4%-7%，目标价由2.1美元下调至2.0美元。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【券商聚焦】招银国际微削知乎(ZH)目标价至2美元 料会员业务增速放缓</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【券商聚焦】招银国际微削知乎(ZH)目标价至2美元 料会员业务增速放缓\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1002821290\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">凤凰网港股 </p>\n<p class=\"h-time\">2023-11-30 15:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>金吾财讯 | 招银国际发研报指，<a href=\"https://laohu8.com/S/ZH\">知乎</a>(ZH)3Q23业绩符合预期，收入同比增长12%，经调整净亏损收窄至2.25亿元人民币。稳健的收入增速主要由强劲的会员业务（同比+39%）和职业教育（同比+86%）所拉动，但部分被疲软的广告业务（同比-17%）拖累。经调整净亏损持续收窄，主要得益于毛利率的提升。展望4Q23，该行预计收入同比下降6%，经调整净亏损为2亿元人民币。职业教育和广告将因季节性和“双11”大促实现环比增长，而会员业务增速或因高基数而放缓（预计同比增长11%）。该行认为，知乎凭借在丰富的IP和内容库方面的优势，能够捕捉短剧和IP内容变现带来的机会。此外，知乎在AI应用方面也取得了不错的进展，志海图AI的应用提高了内容生产力和用户体验。为了反映会员业务的放缓，该行将2023-25年收入下调4%-7%，目标价由2.1美元下调至2.0美元。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZH":"知乎","02390":"知乎-W"},"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=b62e680f0db4db4467b35b8dce01c3f5","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2387141327","content_text":"金吾财讯 | 招银国际发研报指，知乎(ZH)3Q23业绩符合预期，收入同比增长12%，经调整净亏损收窄至2.25亿元人民币。稳健的收入增速主要由强劲的会员业务（同比+39%）和职业教育（同比+86%）所拉动，但部分被疲软的广告业务（同比-17%）拖累。经调整净亏损持续收窄，主要得益于毛利率的提升。展望4Q23，该行预计收入同比下降6%，经调整净亏损为2亿元人民币。职业教育和广告将因季节性和“双11”大促实现环比增长，而会员业务增速或因高基数而放缓（预计同比增长11%）。该行认为，知乎凭借在丰富的IP和内容库方面的优势，能够捕捉短剧和IP内容变现带来的机会。此外，知乎在AI应用方面也取得了不错的进展，志海图AI的应用提高了内容生产力和用户体验。为了反映会员业务的放缓，该行将2023-25年收入下调4%-7%，目标价由2.1美元下调至2.0美元。","news_type":1},"isVote":1,"tweetType":1,"viewCount":2203,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":279796308074616,"gmtCreate":1709331062713,"gmtModify":1709334215160,"author":{"id":"4097226743085970","authorId":"4097226743085970","name":"星元未来","avatar":"https://static.tigerbbs.com/3a8e915d7f808030bbf9731d84347a96","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097226743085970","authorIdStr":"4097226743085970"},"themes":[],"htmlText":"，","listText":"，","text":"，","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/279796308074616","repostId":"2366366393","repostType":2,"repost":{"id":"2366366393","kind":"highlight","pubTimestamp":1694406491,"share":"https://www.laohu8.com/m/news/2366366393?lang=&edition=full","pubTime":"2023-09-11 12:28","market":"hk","language":"zh","title":"“减肥新药”卖爆，销售额同比增363%！小摩：2030年销售额将超千亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2366366393","media":"格隆汇","summary":"国内药企争相布局","content":"<html><body><p><span>减肥药概念股</span>今日表现强劲<span>，</span><span><a href=\"https://laohu8.com/S/300255\">常山药业</a>20cm涨停，<a href=\"https://laohu8.com/S/301509\">金凯生科</a>涨超11%，<a href=\"https://laohu8.com/S/688117\">圣诺生物</a>、<a href=\"https://laohu8.com/S/301393\">昊帆生物</a>、<a href=\"https://laohu8.com/S/688076\">诺泰生物</a>等纷纷冲高。</span></p><p><img src=\"https://img3.gelonghui.com/38fc3-2e63da02-9795-4c8f-9280-98ef2739f0c8.png\"/></p><p>近日司美格鲁肽（商品名：Wegovy）等减肥新药热卖引市场关注，丹麦制药巨头<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>（novo nordisk）超越奢侈品巨头LVMH，成为欧洲市值最高的公司。<span><a href=\"https://laohu8.com/S/LLY\">礼来</a>股价也连番大涨，目前市值已超5500亿美元，是<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>的两倍多。</span></p><p>此外，<a href=\"https://laohu8.com/S/JPM\">摩根大通</a>提高了对减肥药的销售额预测，预计到2030年这种GLP-1激动剂类药物的年销售额将超过1000亿美元，诺和诺德、礼来总市值不断刷创新高。<span><a href=\"https://laohu8.com/S/600030\">中信证券</a>测算，2030年中国减肥用GLP-1受体激动剂的市场规模将达到383亿元。</span></p><h3><font color=\"#3daad6\"><br/></font></h3><h3><font color=\"#3daad6\">“减肥新药”卖爆</font></h3><h3><font color=\"#3daad6\">2023H1销售额同比增长363%</font></h3><div><font color=\"#3daad6\"><br/></font></div><p>2023年8月3日，<em>Science</em>杂志在线发表一篇题为“Turning the tide on obesity”的社论性文章，文中指出：<strong>全球现下有超过十亿人患有肥胖症，超重的比例甚至更多。</strong>随着新型高效减重药物的出现，科学家们正翘首以盼这类药物能否让“肥胖时代”的流行画上历史性的句号。</p><p>世界肥胖联盟在2023年3月公布了最新版《世界肥胖地图》报告，“预计2035年，全球将有超过40亿人超重/肥胖，占全球总人口的一半以上”。</p><p><span>另外一份数据显示，</span><span>帕博利珠单抗全球销售额超120亿美元，首次问鼎“药王”宝座；</span><b>降糖“新宠”司美格鲁肽销售额暴涨363%，一举迈入榜单前三。</b></p><p><img src=\"https://img3.gelonghui.com/0eafd-88f72ae4-2309-40ab-a2bb-571a3f48800f.png\"/></p><p>2023上半年全球畅销药品TOP10</p><p>资料显示，司美格鲁肽由诺和诺德研发，是一款同时获批肥胖和2型糖尿病双适应症的GLP-1激动剂。该药自2017年全球首次上市后，不到6年时间便跻身2023H1全球畅销药TOP3行列。</p><p>目前司美格鲁肽共有3款产品获批在售，分别为Ozempic（注射用降糖药）、Rybelsus（口服降糖药）、Wegovy（注射用减重药），得益于Wegovy销售额的突飞猛进，2023H1同比增长363%，2023上半年已突破90亿美元。<span></span></p><h3><font color=\"#3daad6\"><br/></font></h3><h3><font color=\"#3daad6\">国内多家药企公布GLP-1类药品研发进展</font></h3><div><font color=\"#3daad6\"><br/></font></div><p>6月3日，丹麦药企诺和诺德生产的司<b>美格鲁肽注射液</b>，对肥胖患者的适应症扩容正式获得国家药监局受理。在接下来一年内，该药物可能在国内获批上市。</p><p>据粗略统计，目前国内最少有25家企业，选择以减重为管线进行着GLP-1类药物的研发。</p><p><span>目前，我国唯一获批的GLP-1类减肥药，只有<a href=\"https://laohu8.com/S/000963\">华东医药</a>于今年7月份获批的</span><b>利拉鲁肽注射液。</b><span>司美格鲁肽国内进入3期的有齐鲁，华东，联邦，<a href=\"https://laohu8.com/S/01513\">丽珠医药</a>。</span><span><a href=\"https://laohu8.com/S/01801\">信达生物</a>IBI362（GLP-1R/GCGR 双靶点）目前处于临床3期阶段，恒瑞医药HRS953（GLP-1R/GIPR）临床2期中。</span></p><p><img src=\"https://img3.gelonghui.com/660ea-204a3144-a0bc-43e6-b2c3-5a07d1093e0d.png\"/></p><h3><font color=\"#3daad6\"><br/></font></h3><h3><font color=\"#3daad6\">小摩预测2030年年销售额将超1000亿美元</font></h3><div><font color=\"#3daad6\"><br/></font></div><p>摩根大通分析师Chris Schott表示，他不排除GLP-1在肥胖和糖尿病领域的销售额进一步上升的可能性，在社交媒体的大肆宣传下，这类药物的使用量正在迅速上升。<span></span></p><p>该行预计到2030年这种GLP-1激动剂类药物的年销售额将超过1000亿美元，诺和诺德和礼来形成双寡头垄断。<span></span></p><p><a href=\"https://laohu8.com/S/GS\">高盛</a>在报告中指出，肥胖每年给美国的医疗系统带来1700亿美元的成本，而到2035年，这种慢性疾病的影响将使全球GDP减少4万亿美元，相当于全球第四大经济体德国2022年的GDP，而以GLP-1类疗法为主的减肥药有望给这一趋势带来革命新的改变。</p><div></div><p>该行表示，减肥药物市场将从今年的刚刚超过50亿美元扩大到2030年的440亿美元，翻了近9倍，而这种增长将使诺和诺德和礼来的减肥药大幅受益。</p><p>高盛投资组合经理Jenny Chang表示，减肥药物市场“历史上一直受限”，而随着监管给更更多此类新药“亮绿灯”，使得这批有前景的新药完全可以进入市场。</p><p><a href=\"https://laohu8.com/S/601108\">财通证券</a>指出，相比于传统降糖、减重药物，GLP-1类药物兼具有效性高、安全性佳的优点，近年来利拉鲁肽、司美格鲁肽、替尔泊肽等品种相继上市，可以预计随着推动市场教育进一步加快，将促进GLP-1类药物在降糖、减重人群中渗透率不断提升。</p></body></html>","source":"gelonghui_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>“减肥新药”卖爆，销售额同比增363%！小摩：2030年销售额将超千亿美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n“减肥新药”卖爆，销售额同比增363%！小摩：2030年销售额将超千亿美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-09-11 12:28 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/p/643731><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>减肥药概念股今日表现强劲，常山药业20cm涨停，金凯生科涨超11%，圣诺生物、昊帆生物、诺泰生物等纷纷冲高。近日司美格鲁肽（商品名：Wegovy）等减肥新药热卖引市场关注，丹麦制药巨头诺和诺德（novo nordisk）超越奢侈品巨头LVMH，成为欧洲市值最高的公司。礼来股价也连番大涨，目前市值已超5500亿美元，是辉瑞的两倍多。此外，摩根大通提高了对减肥药的销售额预测，预计到2030年这种GLP...</p>\n\n<a href=\"https://www.gelonghui.com/p/643731\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://img3.gelonghui.com/23bd7-b1ea8c62-e16c-47da-8c4f-414c06832007.jpg","relate_stocks":{"300255":"常山药业","301393":"昊帆生物","301509":"金凯生科","688076":"诺泰生物","688117":"圣诺生物","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","01801":"信达生物","LU0971096721.USD":"富达环球金融服务 A","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","BK0196":"行业龙头","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK0132":"高送转概念","NVO":"诺和诺德","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","BK1589":"北水核心资产","BK4585":"ETF&股票定投概念","SG9999002232.USD":"Allianz Global High Payout USD","000963":"华东医药","BK4007":"制药","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4566":"资本集团","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","BK0229":"化学制品","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK0188":"融资融券","BK4550":"红杉资本持仓","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0187":"一线龙头","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","BK4207":"综合性银行","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0149725797.USD":"汇丰美国股市经济规模基金","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","BK1161":"生物科技","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","BK0175":"白马股","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","JPM":"摩根大通","LU0882574139.USD":"富达环球消费行业基金A ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC"},"source_url":"https://www.gelonghui.com/p/643731","is_english":false,"share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","article_id":"2366366393","content_text":"减肥药概念股今日表现强劲，常山药业20cm涨停，金凯生科涨超11%，圣诺生物、昊帆生物、诺泰生物等纷纷冲高。近日司美格鲁肽（商品名：Wegovy）等减肥新药热卖引市场关注，丹麦制药巨头诺和诺德（novo nordisk）超越奢侈品巨头LVMH，成为欧洲市值最高的公司。礼来股价也连番大涨，目前市值已超5500亿美元，是辉瑞的两倍多。此外，摩根大通提高了对减肥药的销售额预测，预计到2030年这种GLP-1激动剂类药物的年销售额将超过1000亿美元，诺和诺德、礼来总市值不断刷创新高。中信证券测算，2030年中国减肥用GLP-1受体激动剂的市场规模将达到383亿元。“减肥新药”卖爆2023H1销售额同比增长363%2023年8月3日，Science杂志在线发表一篇题为“Turning the tide on obesity”的社论性文章，文中指出：全球现下有超过十亿人患有肥胖症，超重的比例甚至更多。随着新型高效减重药物的出现，科学家们正翘首以盼这类药物能否让“肥胖时代”的流行画上历史性的句号。世界肥胖联盟在2023年3月公布了最新版《世界肥胖地图》报告，“预计2035年，全球将有超过40亿人超重/肥胖，占全球总人口的一半以上”。另外一份数据显示，帕博利珠单抗全球销售额超120亿美元，首次问鼎“药王”宝座；降糖“新宠”司美格鲁肽销售额暴涨363%，一举迈入榜单前三。2023上半年全球畅销药品TOP10资料显示，司美格鲁肽由诺和诺德研发，是一款同时获批肥胖和2型糖尿病双适应症的GLP-1激动剂。该药自2017年全球首次上市后，不到6年时间便跻身2023H1全球畅销药TOP3行列。目前司美格鲁肽共有3款产品获批在售，分别为Ozempic（注射用降糖药）、Rybelsus（口服降糖药）、Wegovy（注射用减重药），得益于Wegovy销售额的突飞猛进，2023H1同比增长363%，2023上半年已突破90亿美元。国内多家药企公布GLP-1类药品研发进展6月3日，丹麦药企诺和诺德生产的司美格鲁肽注射液，对肥胖患者的适应症扩容正式获得国家药监局受理。在接下来一年内，该药物可能在国内获批上市。据粗略统计，目前国内最少有25家企业，选择以减重为管线进行着GLP-1类药物的研发。目前，我国唯一获批的GLP-1类减肥药，只有华东医药于今年7月份获批的利拉鲁肽注射液。司美格鲁肽国内进入3期的有齐鲁，华东，联邦，丽珠医药。信达生物IBI362（GLP-1R/GCGR 双靶点）目前处于临床3期阶段，恒瑞医药HRS953（GLP-1R/GIPR）临床2期中。小摩预测2030年年销售额将超1000亿美元摩根大通分析师Chris Schott表示，他不排除GLP-1在肥胖和糖尿病领域的销售额进一步上升的可能性，在社交媒体的大肆宣传下，这类药物的使用量正在迅速上升。该行预计到2030年这种GLP-1激动剂类药物的年销售额将超过1000亿美元，诺和诺德和礼来形成双寡头垄断。高盛在报告中指出，肥胖每年给美国的医疗系统带来1700亿美元的成本，而到2035年，这种慢性疾病的影响将使全球GDP减少4万亿美元，相当于全球第四大经济体德国2022年的GDP，而以GLP-1类疗法为主的减肥药有望给这一趋势带来革命新的改变。该行表示，减肥药物市场将从今年的刚刚超过50亿美元扩大到2030年的440亿美元，翻了近9倍，而这种增长将使诺和诺德和礼来的减肥药大幅受益。高盛投资组合经理Jenny Chang表示，减肥药物市场“历史上一直受限”，而随着监管给更更多此类新药“亮绿灯”，使得这批有前景的新药完全可以进入市场。财通证券指出，相比于传统降糖、减重药物，GLP-1类药物兼具有效性高、安全性佳的优点，近年来利拉鲁肽、司美格鲁肽、替尔泊肽等品种相继上市，可以预计随着推动市场教育进一步加快，将促进GLP-1类药物在降糖、减重人群中渗透率不断提升。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1216,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":271491973595304,"gmtCreate":1707319982817,"gmtModify":1707320227928,"author":{"id":"4097226743085970","authorId":"4097226743085970","name":"星元未来","avatar":"https://static.tigerbbs.com/3a8e915d7f808030bbf9731d84347a96","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097226743085970","authorIdStr":"4097226743085970"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$&nbsp;</a>","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$&nbsp;</a>","text":"$Faraday Future(FFIE)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/271491973595304","isVote":1,"tweetType":1,"viewCount":506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":621963335,"gmtCreate":1671810861927,"gmtModify":1671811143935,"author":{"id":"4097226743085970","authorId":"4097226743085970","name":"星元未来","avatar":"https://static.tigerbbs.com/3a8e915d7f808030bbf9731d84347a96","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097226743085970","authorIdStr":"4097226743085970"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/621963335","repostId":"1115397926","repostType":4,"isVote":1,"tweetType":1,"viewCount":2105,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}